Triple-negative breast cancer (TNBC), accounting for 10%–17% among all BCs, is a special subtype characterized by negative human epidermal growth factor receptor 2 (HER2), progesterone receptor (PR), and estrogen receptor (ER) (Lin et al., 2012). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.